1. The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic progression-free survival for metastatic hormone-sensitive prostate ...
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
1. In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while accounting for ...
1. In this surveillance study, the incidence rates of several cancers increased among both younger and older adults in many ...
1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia ...
Imfinzi Combo Cuts Gastric Cancer Risk by Twenty Nine Percent Earlier this week at the American Society of Clinical Oncology ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Jessie ...
1. In this randomized clinical trial, exercise was significantly associated with improved sexual function in men with prostate cancer. 2. ...
1. In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with wide variation ...
1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
